J&J Just Torched $5 Billion in CAR-T Progress. Nobody Saw It Coming.

And to be fair, the neighborhood is crowded. Bristol Myers Squibb has Abecma and Breyanzi. Novartis pioneered the space with Kymriah. Gilead's Kite Pharma is quadrupling its global manufacturing capacity by 2026. Everyone is racing to expand, and the B-cell lymphoma CAR-T market is becoming a street brawl.

But J&J isn't leaving cell therapy entirely. It still has Carvykti, its BCMA-targeted CAR-T developed with Legend Biotech for multiple myeloma. Carvykti is a monster: Q4 2025 sales hit $555 million, up 66% year-over-year. More than 9,000 patients have been treated. It's on track for $1.6 to $2.0 billion in 2025 sales.

So the real calculus might be simpler than it looks. J&J already has a CAR-T winner. Building a second CAR-T franchise in a hyper-competitive indication, with all the manufacturing headaches and reimbursement nightmares that come with it, may have looked like a bad bet even with great data.

The Ugly Economics Behind the Scenes

This is where the story gets bigger than one company's decision. CAR-T therapy has an economics problem, and J&J's exit is a symptom.

Manufacturing a single dose of autologous CAR-T (where you harvest a patient's own cells, engineer them, and infuse them back) costs between $100,000 and $200,000. The list price for approved CAR-T products ranges from $373,000 to $475,000. But that's just the drug. By the time you add hospitalization, lymphodepletion chemotherapy, ICU stays for side effects, and follow-up care, total costs can reach $1 to $2 million per patient.

Medicare reimbursement doesn't come close to covering that. For fiscal year 2026, base payments for trial-associated CAR-T cases sit around $50,000. Some hospitals are actively deprioritizing under-reimbursed CAR-T trials because they lose money on every patient.

Imagine opening a restaurant where every meal costs you $200 to make, you charge $400, but your biggest customer only pays $50. That's CAR-T economics in 2026.

J&J may have looked at those numbers for B-cell lymphoma, a space with four established competitors and squeezed margins, and decided Carvykti's myeloma franchise was the better bet. One blockbuster is plenty when each new CAR-T program requires its own manufacturing infrastructure, regulatory pathway, and commercial build-out.

What This Means for the CAR-T Space

J&J's exit sends a clear signal: stellar clinical data is no longer enough to justify a CAR-T program. The commercial math has to work, too. And in an indication where BMS, Novartis, and Gilead are already entrenched, late entrants face a brutal climb.

The companies still in the race are doubling down on scale. Gilead is massively expanding production. BMS is investing in automation. The message from all of them is the same: manufacturing capacity is the moat, not just clinical data.

Meanwhile, the next frontier (allogeneic, or "off-the-shelf" CAR-T products that don't require harvesting each patient's cells) promises to slash costs by an order of magnitude. Companies working on universal CAR-T platforms, in vivo CAR-T generation, and point-of-care manufacturing are all chasing the dream of dramatically lower per-dose costs. If they get there, today's autologous economics will look prehistoric.

The Bottom Line

J&J didn't kill this program because the science failed. It killed it because the business case didn't clear the bar in a market that's getting more expensive and more competitive by the quarter. The company is betting that concentrating firepower on Carvykti, plus its broader oncology pipeline targeting $50 billion in sales by decade's end, will pay off better than fighting for lymphoma market share.

For patients enrolled in the terminated trials, J&J says support will continue. For the rest of the cell therapy world, the lesson is sobering: in 2026, even a therapy that works better than anything on the market can get shelved if the spreadsheet doesn't cooperate.

The science of CAR-T has never been stronger. The business of CAR-T has never been harder.

One Failed Trial Just Gutted Indivior's Entire R&D Operation

Indivior's experimental opioid addiction drug flopped in Phase 2, and now the company is gutting its research team. Wall Street didn't flinch, but the long-term implications of becoming a one-drug company are harder to ignore.